20s Proteasome – Pipeline Review, H2 2017

Global Markets Direct’s, ‘20s Proteasome – Pipeline Review, H2 2017’, provides in depth analysis on 20s Proteasome targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 20s Proteasome targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders, Non Malignant Disorders and Women's Health under development targeting 20s Proteasome.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for 20s Proteasome

The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects

The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 20s Proteasome targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 20s Proteasome

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc

Celgene Corp

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

20s Proteasome - Overview 6

20s Proteasome - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 12

Products under Development by Universities/Institutes 16

20s Proteasome - Therapeutics Assessment 18

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

20s Proteasome - Companies Involved in Therapeutics Development 22

Amgen Inc 22

Celgene Corp 24

20s Proteasome - Drug Profiles 25

carfilzomib - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

marizomib - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

oprozomib - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecule to Inhibit 20s Proteasome for Tuberculosis - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

VPE-001 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

VPEA-002 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

VPEA-004 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

20s Proteasome - Dormant Products 50

20s Proteasome - Product Development Milestones 51

Featured News & Press Releases 51

Aug 30, 2017: FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS (Carfilzomib) Label 51

Aug 30, 2017: Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma 51

Aug 23, 2017: Overall Survival Analysis From KYPROLIS Phase 3 Endeavor Trial Published In The Lancet Oncology 52

Aug 08, 2017: Scottish Medicines Consortium Accepts Amgen's Multiple Myeloma Treatment, KYPROLIS (carfilzomib), in Combination with Dexamethasone, for use at First Relapse 53

Aug 07, 2017: Amgen’s Kyprolis accepted for use in NHS Scotland 54

Jul 24, 2017: Novocure Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune as Adjuvant Therapy in Patients with Glioblastoma 54

Jul 19, 2017: NICE approves more tolerable treatment for blood cancer 55

Jul 14, 2017: Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS (Carfilzomib) Label 55

Jul 12, 2017: Second Phase 3 Study Shows KYPROLIS (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma 56

Jun 21, 2017: Amgen To Present New Data on KYPROLIS At 22nd Congress of the European Hematology Association 57

Jun 13, 2017: Amgen's Multiple Myeloma Treatment, KYPROLIS (Carfilzomib), in Combination with Dexamethasone, Receives NICE Recommendation for Use at First Relapse 57

May 18, 2017: ONO Receives Supplemental Manufacturing and Marketing Approval of KYPROLIS for Intravenous Injection 10 mg and 40 mg, a Proteasome Inhibitor, in Relapsed or Refractory Multiple Myeloma 58

Mar 03, 2017: Amgen Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop 59

Mar 01, 2017: Amgen To Present New KYPROLIS (Carfilzomib) Data At The 16th International Myeloma Workshop 60

Feb 28, 2017: Phase 3 Head-to-Head Trial Showed KYPROLIS (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients 61

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indications, H2 2017 10

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 15

Number of Products under Investigation by Universities/Institutes, H2 2017 16

Products under Investigation by Universities/Institutes, H2 2017 17

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Stage and Route of Administration, H2 2017 20

Number of Products by Stage and Molecule Type, H2 2017 21

Pipeline by Amgen Inc, H2 2017 23

Pipeline by Celgene Corp, H2 2017 24

Dormant Projects, H2 2017 50

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Routes of Administration, H2 2017 19

Number of Products by Stage and Routes of Administration, H2 2017 19

Number of Products by Stage and Molecule Type, H2 2017 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports